16
Mar
2023

Pfizer Acquires Seagen, Sanofi & Novo Cut Insulin Prices, & Illumina’s Proxy Fight

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Alumis & BioNTech Stumble, Lilly Buys Merida, & Takeda’s Latest FDA Approval
RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill